Overview of the main methods used to combine proteins with nanosystems: Absorption, bioconjugation, and encapsulation

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 37-49

  Marco, Mariagrazia Di ^a   Shamsuddin, Shaharum ^b   Razak, Khairunisak Abdul ^c   Aziz, Azlan Abdul ^d   Devaux, Corinne ^a   Borghi, Elsa ^a   Levy, Laurent ^a   Sadun, Claudia ^e  

^a NANOBIOTIX   (France)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

^c SCHOOL OF MATERIALS AND MINERAL RESOURCES ENGINEERING   (Malaysia)

^d SCHOOL OF PHYSICS   (Malaysia)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Absorption; Bioconjugation; Drug delivery; Encapsulation; Nanoparticles; Polypeptides; Proteins

Indexed keywords

ALGINIC ACID; ARGINYLGLYCYLASPARTIC ACID; CHITOSAN; HEPATITIS A VACCINE; LIPOSOME; NANOPARTICLE; POLYGLACTIN; POLYLACTIC ACID; SILICON DIOXIDE;

BIOCOMPATIBILITY; CROSS LINKING; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; METHODOLOGY; NANOENGINEERING; PROTEIN DENATURATION; PROTEIN ENGINEERING; PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW;

ABSORPTION; DRUG COMPOUNDING; NANOCAPSULES; NANOMEDICINE; PROTEINS;

EID: 77951190722     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Navalakhe RM, Nandedkar TD. Application of nanotechnology in biomedicine. Indian J Exp Biol. 2007;45:160-165.
2. Engel E, Michiardi A, Navarro M, et al. Nanotechnology in regenerative medicine: the materials side. Trends Biotechnol. 2008;26:39-47.
3. Heath JR, Davis ME. Nanotechnology and Cancer. Annu Rev Med. 2008;59:251-265.
4. Melendi PG, Ferna R, Pacheco RF, et al. Nanoparticles as smart treatment-delivery systems in plants: Assessment of different techniques of microscopy for their visualization in plant tissues. Ann Bot. 2008; 101:187-195.
5. Gidaspow D, Jiradilok V. Nanoparticle gasifier fuel cell for sustainable energy future. J Power Source. 2007;166:400-410.
6. Chen D, Qiao X, Qiu X, et al. Synthesis and electrical properties of uniform silver nanoparticles for electronic applications. J Mat Sci. 2009;44:1076-1081.
7. Medintz IL, Uyeda HT, Goldman ER, et al. Quantum dot bioconjugates for imaging, labeling and sensing. Nat Mater. 2005;4:435-446.
8. Corot C, Robert P, Idée JM, et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006;58:1471-1504.
9. De la Fuente JM, Berry CC, Riehle MO, et al. Nanoparticle targeting at cells. Langmuir. 2006;22:3286-3293.
10. Alonso MJ. Nanoparticulate drug carrier technology. In: Cohen S, Bernstein H, editors. Microparticulate Systems for the Delivery of Proteins and Vaccines. New York, NY: Marcel Dekker; 1996. p. 203-242.
11. Drexler KE. Molecular engineering: an approach to the development of general capabilities for molecular manipulation. Proc Natl Acad Sci USA. 1981;78:5275-5278.
12. Rajagopal K, Schneider JP. Self-assembling peptides and proteins for nanotechnological applications. Curr Opin Struct Biol. 2004;14: 480-486.
13. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeu- tics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther. 2006;5:1909-1917.
14. Nelson DL, Cox MM. Lehninger Principles of Biochemistry, 4th Edition. New York, NY: W H Freeman; 2004.
15. Liang FH, Hong MH, Ho RM, et al. Novel method using a temperature- sensitive polymer (methylcellulose) to thermally gel aqueous alginate as a pH-sensitive hydrogel. Biomacromolecules. 2004;5:1917-1925.
16. Tan ML, Choong PFM, Dass CR. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides. Oct 9. [Epub ahead of print].
17. Ferrari M, Downing G. Medical nanotechnology: shortening clinical trials and regulatory pathways? Biodrugs. 2005;19:203-210.
18. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Delivery Rev. 2007;59:478-490.
19. Martins Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery: liposomes versus lipid nanoparticles. Int J Nanomed. 2007;2:595-607.
20. Chen H, Langer R. Oral particulate delivery: status and future trends. Adv Drug Del. 1998;34:339-350.
21. Delie F, Blanco-Príeto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules. 2005;10:65-80.
22. Borchard G, Luegen HL, de Boer AG, et al. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J Control Release. 1996;39:131-138.
23. Malik DK, Baboota S, Ahuja A, et al. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv. 2007;4:141-151.
24. des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006;116:1-27.
25. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J Control Release. 2009;135:144-151.
26. Couvreur P, Lenaerts V, Kante B, et al. Oral and parenteral administration of insulin associated to hydrolysable nanoparticles. Acta Pharm Technol. 1980;26:220-222.
27. Aboubakar M, Couvreur P, Pinto-Alphandary H, et al. Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation. Drug Develop Res. 2000;49:109-117.
28. Carino GP, Jacob JS, Mathiowitz E. Nanospheres based oral insulin delivery. J Control Release. 2000;65:261-269.
29. Kim JH, Kim YS, Park K, et al. Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials. 2008;29:1920-1930.
30. Zhang S, Doschak MR, Uluda H. Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. Biomaterials. 2009;30:5143-5155.
31. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90:261-280.
32. Frokjaer S, Hovgaard L. Pharmaceutical Formulation Development of Peptides and Proteins. Andover, UK: Taylor and Francis; 2000.
33. Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release. 2005;108:244-262.
34. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth fac- tor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30:5737-5750.
35. ® ABI-007) in the treatment of breast cancer. Int J Nanomed. 2009;4:99-105.
36. Huh YM. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc. 2005;127:12387-12391.
37. DeNardo SJ, De Nardo GL, Miers LA, et al. Development of tumor targeting bioprobes (In-chimeric L6 mAb nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res. 2005;11:7087-7092.
38. Aktaş Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem. 2005;16:1503-1511.
39. Zhao X, Hilliard LR, Merchery SJ, et al. A rapid bioassay for single bacterial cell quantitation using bioconjugated nanoparticle. Proc Natl Acad Sci USA. 2004;101:5027-5032.
40. Natarajan A, Xiong CY, Gruattner C, et al. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biol Ther. 2008;23:82-90.
41. Bhatia SN, Balis UJ, Yarmush ML, et al. Effect of cell-cell interactions in preservation of cellullar phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 1999;13:1883-1900.
42. Anderson JM. Biological responses to materials. Annu Rev Mater Res. 2001;31:81-110.
43. Hench LL, Polak JM. Third-generation biomedical materials. Sci. 2002;295:1014-1017.
44. Allen LT, Fox EJP, Blute I, et al. Interaction of soft condensed Interaction of soft condensed materials with living cells: phenotype/transcriptome correlations for the hydrophobic effect. Proc Natl Acad Sci USA. 2003;100:6331-6336.
45. Heungsoo S, Seongbong J, Mikos AG. Biomimetic materials for tissue engineering. Biomaterials. 2003;24:4353-4364.
46. Tsuda Y, Kikuchi A, Yamato M, et al. Control of cell adhesion and detachment using temperature and thermoresponsive copolymer grafted culture surfaces. J Biomed Mater Res. 2004;69A:70-78.
47. Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle- protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA. 2007;104: 2050-2055.
48. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311:622-627.
49. Lynch I, Dawson KA, Linse S. Detecting cryptic epitopes created by nanoparticles. Sci STKE. 2006; 327: pe14.
50. Lynch I, Cedervall T, Lundqvist M, et al. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci. 2007;134-135:167-174.
51. Ahmad A, Evans HM, Ewert K, et al. New multivalent cationic lipids reveal bell curve for transfection efficiency versus membrane charge density: lipid-DNA complexes for gene delivery. J Gene Med. 2005;7:739-748.
52. ®) coupled nanoparticles. Inter J Pharm. 2007;331:190-196.
53. Kocbek P, Obermajer N, Cegnar M, et al. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120:18-26.
54. Tirrel M, Kokkoli E, Biesalski M. The role of surface science in bioengineered materials. Surf Sci. 2002;500:61-83.
55. Vroman L, Adams AL. Identification of rapid changes at plasma-solid interfaces. J Biomed Mater Res. 1969;3:43-67.
56. Young BR, Lambrecht LK, Mosher DF, et al. Plasma proteins: Their role in initiating platelet and fibrin deposition on biomaterials. In: Cooper SL, Peppas NA, editors. Biomaterials: Interfacial phenomena and applications. Washington, DC: American Chemical Society: 1982;199:317-349.
57. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long- circulating polymeric nanospheres. Science. 1994;263:1600-1603.
58. Owens DE, Peppas NA. Opsonization, biodistribution, and phar- macokinetics of polymeric nanoparticles. Int J Pharm. 2006;307: 93-102.
59. Frank M, Fries L. The role of complement in inflammation and phagocytosis. Immunol Today. 1991;12:322-326.
60. Lynch I, Dawson K A. Protein-nanoparticle interactions. Nano Today. 2008;3:40-47.
61. Dutta D, Sundaram SK, Teeguarden JG, et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci. 2007;100:303-315.
62. Illum L, Hunneybal IM, Davis SS. The effect of hydrophilic coatings on the uptake of colloidal particles by the liver and by peritonealmacrophages. Int J Pharm. 1986;29:53-65.
63. Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res. 2002;19: 1061-1067.
64. Aggarwal P, Hall JB, McLeland CB, et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Del Rev. 2009;61:428-437.
65. Arai T, Norde W. The behavior of some model proteins at solid-liquid interfaces. II. Sequential and competitive absorption. Colloid Surf. 1990;51:17-28.
66. Linse S, Cabaleiro-Lago C, Xue WF, et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci USA. 2007;104: 8691-8696.
67. Bellezza F, Cipiciani A, Quotadamo MA, et al. Structure, stability, and activity of myoglobin adsorbed onto phosphate-grafted zirconia nanoparticles. Langmuir. 2007;23:13007-13012.
68. Podolski IY, Podlubnaya ZA, Kosenko EA, et al. Effects of hydrated forms of C60 fullerene on amyloid b-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol. 2007;7:1479-1485.
69. Chien P, Weissman JS, DePace AH. Emerging principles of conformation- based prion inheritance. Annu Rev Biochem. 2004;73:617-656.
70. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Ann Rev Biochem. 2006;75:333-366.
71. Dobson CM. The structural basis of protein folding and its link with human disease. Philos Trans R Soc Lond B Biol Sci. 2001;356:133-145.
72. Koo EH, Lansbury PT Jr, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA. 1999;96:9989-9990.
73. Floege J, Ehlerding G. Beta-2-microglobulin associated amyloidosis. Nephron. 1996;72:9-26.
74. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). Risk Assessment of Products of Nanotechnologies. Brussels, Belgium: European Commission; 2009. p. 1-71.
75. Chun AL. Nanoparticles: Coat of proteins. Nat Nanotechnology. 2008.
76. Klein J. Probing the interactions of proteins and nanoparticles. Proc Natl Acad Sci USA. 2007;104:2029-2030.
77. Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein corona with possible implica- tions for biological impacts. Proc Natl Acad Sci USA. 2008;105: 14265-14270.
78. Martins MCL, Ratner BD, Barbosa MA. Protein absorption on mixtures of hydroxyl-and methyl-terminated alkanethiols self-assem- bleted monolayers. J Biomed Mater Res Pt A. 2003;67A:158-171.
79. Phillips MC, Evans MTA, Graham DE, et al. Structure and properties of protein films adsorbed at the air-water interface. Colloid Polym Sci. 1975;253:424-427.
80. Brash JL, Horbett TA, editors. Proteins at Interfaces: Physicochemical and biochemical studies. Advanced Symposium Series, 343. Washington, DC: American Chemical Society; 1987. http://catalogue.nla.gov.au/Record/36034.
81. Horbett TA, Brash JL, editors. Proteins at Interfaces II: Fundamentals and application. Advanced Symposium Series, 602. Washington, DC: American Chemical Society; 1995. http://searchworks.stanford.edu/view/3082531.
82. Hlady V, Buijs J. Protein absorption on solid surfaces. Curr Opin Biotechnol. 1996;7:72-77.
83. Sigal GB, Mrksich M, Whitesides GM. Effect of surface wetability on the absorption of proteins and detergents. J Am Chem Soc. 1998;120:3464-3473.
84. Waner MJ, Gilchrist M, Schindler M, et al. Imaging the molecular dimensions and oligomerization of proteins at liquid/solid interfaces. J Phys Chem B. 1998;102:1649-1657.
85. Gray JJ. The interaction of protein with solid surfaces. Curr Opin Struct Biol. 2004;14:110-115.
86. Wang D, Douma M, Swift B, et al. The absorption of globular protein onto a fluorinated PDMS surface. J Colloid Interface Sci. 2009;331: 90-97.
87. Andrade JD, Hlady V, Wei AP. Absorption of complex proteins at interfaces. Pure Appl Chem. 1992;64:1777-1781.
88. Andrade JD, Hlady V. Protein absorption and materials biocompat- ibility: A tutorial review and suggested hypothesis. Adv Polym Sci. 1986;79:1-63.
89. Collier TO, Jenney CR, Defife KM, et al. Protein absorption on chemi- cally modified surfaces. Biomed Sci Instrum. 1997;33:178-183.
90. Moulin AM, O'Shea SJ, Badley RA, et al. Measuring surface- induced conformational changes in proteins. Langmuir. 1999;15: 8776-8779.
91. Holt SA, McGillivray DJ, Poon S, et al. Protein deformation and surfactancy at an interface. J Phys Chem B. 2000;104:7431-7438.
92. Henderson MJ, Perriman AW, Robson-Marsden H, et al. Protein- poly(silicic)acid interactions at the air/solution interface. J Phys Chem B. 2005;109:20878-20886.
93. Perriman AW, Henderson MJ, Holt SA, et al. Effect of the air-water interface on the stability of ß-Lactoglobulin. J Phys Chem B. 2007;111: 13527-13537.
94. Norde W, MacRitchie F, Nowicka G, et al. Protein absorption at solid liquid interfaces: Reversibility and conformation aspects. J Colloid Interface Sci. 1986;112:447-456.
95. Hayens CA, Norde W. Structures and stabilities of adsorbed proteins. J Colloid Interface Sci. 1995;169:313-328.
96. Nakanishi K, Sakiyama T, Imaura K. On the absorption of proteins on solid surfaces, a common but very complicated phenomenon. J Biosc Bioeng. 2001;91:233-244.
97. Roach P, Farrar D, Perry CC. Interpretation of protein absorption: surface-induced conformational changes. J Am Chem Soc. 2005;127: 8168-8173.
98. Niemeyer CM. Semi-synthetic DNA-protein conjugates: Novel tools in analytics and nanobiotechnology. Nucleic acids chemistry and biology. Biochem Soc Trans. 2004;32:51-53.
99. Shinkai M. Functional magnetic particles for medical application. J Biosci Bioeng. 2002;94:606-613.
100. Wang L, Zhao W, Tan W. Bioconjugated silica nanoparticles: Development and applications. Nano Res. 2008;1:99-115.
101. Bharali DJ, Ilona K, Ewa KS, et al. Organically modified silica nanopar- ticles: A nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci USA. 2005;102:11539-11544.
102. Arruebo M, Fernandez-Pacheco R, Velasco B, et al. Antibody-functionalized hybrid superparamagnetic nanoparticles. Adv Funct Mater. 2007;17: 1473-1479.
103. Aytur T, Foley J, Anwar M, et al. A novel magnetic bead bioassay plat- form using a microchip-based sensor for infectious disease diagnosis. J Immunol Methods. 2006;314:21-29.
104. Zhao X, Tapec-Dytioco R, Wang K, et al. Collection of trace amounts of DNA/mRNA molecules using genomagnetic nanocapturers. Anal Chem. 2003;75:3476-3483.
105. Thirumamagal BTS, Zhao XB, Bandyopadhyaya AK, et al. Receptor- targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem. 2006;17:1141-1150.
106. Hermanson GT. Bioconjugate Techniques. San Diego, CA: Academic Press; 1996.
107. Graham DE, Harich KC, White RH. Reductive dehalogenation of monobromobimane by tris(2-carboxyethyl)phosphine. Anal Biochem. 2003;318:325-328.
108. Simonian AL, Good TA, Wang SS, et al. Nanoparticle-based optical biosensors for the direct detection of organophosphate chemical warfare agents and pesticides. Anal Chim Acta. 2005;534: 69-77.
109. Sun EY, Josephson L, Kelly KA, et al. Development of nanoparticle libraries for biosensing. Bioconjug Chem. 2006;17:109-113.
110. Grüttner C, Müller K, Teller J, et al. Synthesis and antibody conjuga- tion of magnetic nanoparticles with improved specific power absorp- tion rates for alternating magnetic field cancer therapy. J Magn Magn Mater. 2007;311:181-186.
111. Aubin-Tam ME, Schifferli KA. Structure and function of nanoparticle- protein conjugates. Biomed Mater. 2008;3(3):034001.
112. Weber C, Reiss S, Langer K. Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups. Int J Pharm. 2000;211:67-78.
113. Derek B, Smyth DG. Reactions of N-ethylmaleimide with peptides and amino acids. Biochem J. 1964;91:589-595.
114. Jameson DM, Wong S. Chemistry of Protein Conjugation and Cross-linking. 2nd Ed. Baton Rouge, FL: CRC Press; 2009.
115. Madison LD, Rosenzweig SA, Jamieson JD. Use of the heterobifunc- tional cross-linker rn-maleimidobenzoyl N-hydroxysuccinimide ester to affinity label cholecystokinin binding proteins on rat pancreatic plasma membranes. J Biol Chem. 1984;259:1481-1482.
116. Mattson G, Conklin E, Desai S, et al. A practical approach to crosslinking. Mol Biol Reports. 1992;17:167-183.
117. Golemis E. Protein-Protein Interactions. A molecular cloning manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2002.
118. Xing Y, Rao Y. Quantum dot bioconjugates for in vitro diagnostics and in vivo imaging. Cancer Biomark. 2008;4:307-319.
119. Jonkheijm P, Weinrich D, Schröder H, et al. Chemical strategies for generating protein biochips. Angew Chem Int Ed. 2008;47:9618-9647.
120. Cleland WW. Dithiothreitol, a new protective reagent for SH groups. Biochemistry. 1964;3:480-482.
121. Traut RR, Bollen A, Sun TT, et al. Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome. Biochemistry. 1973;12:3266-3273.
122. Langer K, Coester C, Weber C, et al. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur J Pharm Biopharm. 2000;49:303-307.
123. Wang S, Mamedova N, Kotov NA, et al. Antigen/antibody immunocomplex from CdTe nanoparticle bioconjugates. Nano Lett. 2002;2:817-822.
124. Gonzalez M, Bagatolli LA, Echabe I, et al. Interaction of biotin with streptavidin. Thermostability and conformational changes upon binding. J Biol Chem. 1997;272:11288-11294.
125. Green NM. Avidin and streptavidin. Method Enzymol. 1990;184:51-67.
126. Parka JA, Lee JJ, Kim IS, et al. Magnetic and MR relaxation properties of avidin-biotin conjugated superparamagnetic nanoparticles. Colloid Surf A. 2008;313-314:288-291.
127. Langer K, Coester C, Weber C, et al. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eu J Pharm Biopharm. 2000;49:303-307.
128. Coester C, Kreuter J, von Briesen H, et al. Preparation of avidin- labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int J Pharm. 2000;196:147-149.
129. Gole A, Dash C, Soman C, et al. On the preparation, characterization, and enzymatic activity of fungal proteasegold colloid bioconjugates. Bioconjug Chem. 2001;12:684-690.
130. Kudelski A. Influence of electrostatically bound proteins on the structure of linkage monolayers: absorption of bovine serum albumin on silver and gold substrates coated with monolayers of 2-mercaptoethanesulphonate. Vib Spectrosc. 2003;33:197-204.
131. Alliegro MC. Effects of dithiothreitol on protein activity unrelated to thiol-disulfide exchange: for consideration in the analysis of protein function with Cleland's reagent. Anal Biochem. 2000;282: 102-106.
132. Shenoy BC, Appu Rao AG, Raghavendra Rao MR. Effect of chemical modification on structure and activity of glucoamylase from Aspergillus candidus and Rhizopus species. J Biosci. 1987;11: 339-350.
133. Diagaradjane P, Orenstein-Cardona JM, Colon-Casasnovas NE, et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin Cancer Res. 2008;14:731-741.
134. Kisel MA, Kulik LN, Tsybovsky IS, et al. Liposomes with phospha- tidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105-115.
135. Gluck R. Liposomal hepatitis A vaccine and liposomal multiantigen combination vaccines. J Lipo Res. 1995;5:467-469.
136. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995;13:527-537.
137. Colletier JP, Chaize B, Winterhalter M, et al. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. 2002;2:1-8.
138. Ruysschaert T, Germain M, da Silva Gomes JFP. Liposome-based nanocapsules. IEEE Trans Nanobioscience. 2004;3:49-55.
139. Besanger TR, Brennan JD. Entrapment of membrane proteins in Sol Gel derived silica. J Sol Gel Sci Techn. 2006;40:209-225.
140. Tan W, Wang K, He X, et al. Bionanotechnology based on silica nanoparticles. Med Res Rev. 2004;24:621-638.
141. Nandiyanto ABD, Kim SG, Iskandar F, et al. Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters. Micropor Mesopor Mat. 2009;120: 447-453.
142. Lu B, Smyth MR, O'Keneddy JR. Immunological activities of IgG antibody on pre-coated Fc receptor surfaces. Anal Chim Acta. 1996;331:97-102.
143. Vanderberg ET, Brown RS, Krull UJ. Immobilized enzymes and cells in biochemical reactions. In: Veliky IE, McLean RJC, editors. Immobilized Biosystems: Theory and Practical Applications. Amsterdam, Holland: Elsevier; 1983.
144. Narayanan SS, Sarkar R, Pal SK. Structural and functional characterization of enzyme quantum dots conjugates: covalent attachment of CdS nanocryrtal to α-chemo trypsin. J Phys Chem C. 2007;111:11539-11543.
145. Menaa B, Herrero M, Rives V, Lavrenko M, Eggers DK. Favourable influence of hydrophobic surfaces on protein structure in porous organically-modified silica glasses. Biomaterials. 2008;29:2710-2718.
146. Seeherman H, Wozney J, Li R. Bone morphogenetic protein delivery systems. Spine. 2002;27:16-23.
147. Janes KA, Calvo P, Alonso MJ. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev. 2001;47:83-97.
148. Gombotz VR, Pettit DK. Biodegradable polymers for protein and peptide drug delivery. Bioconjug Chem. 1995;6:332-351.
149. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24.
150. Crotts G, Park TG. Protein delivery from poly(lactic-coglycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul. 1998;15:699-713.
151. Zheng CH, Goa JQ, Zhang YP, Liang WQ. A protein delivery system: biodegradable alginate-chitosan-poly(lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun. 2004;323: 1321-1327.
152. Sun-Woong K, Oju J, Byung-Soo K. Tissue Eng. 2005;11:438-447.
153. Lee ES, Park KH, Park IS, et al. Glycol chitosan as a stabilizer for protein encapsulated into poly(lactide-co-glycolide) microparticle. Int J Pharm. 2007;338:310-316.
154. Xu P, Gullotti E, Tong L, et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm. 2009;6:190-201.
155. Fu K, Griebenow K, Hsieh L, et al. FTIR characterization of the secondary structure of proteins encapsulated with PLGA microspheres. J Control Release. 1999;58:357-366.
156. Diwan M, Park TG. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Control Release. 2001;73: 233-244.
157. Kang J, Schwendeman SP. Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(d,l-lactide-co-glycolide) implants. Biomaterials. 2002;23:239-245.
158. Van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2004;17: 1159-1167.
159. Vila A, Sanchez A, Tobio M, et al. Design of biodegradable particles for protein delivery. J Control Release. 2002;78:15-24.
160. Calvo P, Remuñan-López C, Vila-Jato JL, et al. Chitosan and chitosan/ ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;14: 1431-1436.
161. Calvo P, Remunan-Lopez C, Vila-Jato JL, et al. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polymer Sci. 1997;63:125-132.
162. Calvo P, Remunan-Lopez C, Vila-Jato JL, et al. Chitosan and chitosan/ ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res. 1997;14: 1431-1436.
163. Amidi M, Romeijn SG, Borchard G, et al. Preparation and character- ization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release. 2006;111:107-116.
164. Sarmento B, Ferreira DC, Jorgensen L, et al. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles. Eur J Pharm Biopharm. 2007;65:10-17.
165. Li T, Shi XW, Du YM, et al. Quaternized chitosan/alginate nanoparticles for protein delivery. J Biomed Mater Res A. 2007;83:383-390.
166. Schoubben A, Blasi P, Giovagnoli S, et al. Novel composite microparticles for protein stabilization and delivery. Eur J Pharm Sci. 2009;36:226-234.
167. Nakai H, Richardson CC. The gene 1.2 protein of bacteriophage T7 interacts with the E. coli dGTP triphosphohydrolase to form a GTP-binding protein. J Biol Chem. 1990;265:4411-4419.
168. Evans PR, Farrants GW, Hudson PJ. Phosphofructokinase: Structure and control. Philos Trans R Soc Lond B Biol Sci. 1981;293:53-62.
169. Hill RL, Brew K. Lactose synthetase. Adv Enzymol. 1975;43: 411-490.
170. Srere PA. Complexes of sequential metabolic enzyme. Ann Rev Biochem. 1987;56:89-124.
171. Prelich G, Tan CK, Kostura M, et al. Functional identity of proliferating cell nuclear antigen and a DNA Polymerase-δ auxiliary protein. Nature. 1989;326:517-520.